Free tool
FAERS Monitor: Lazcluze
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219008 or its brand name (Lazcluze, Lazertinib Mesylate). Reports on generic versions are filed under their own applications.
Reports
865
Serious
621
72% of reports
Hospitalization
211
Death reported
35
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- rash162
- infusion related reaction96
- paronychia69
- off label use60
- neuropathy peripheral53
- fatigue46
- diarrhoea41
- nausea36
- pruritus35
- stomatitis32
- dermatitis acneiform31
- dyspnoea29
- decreased appetite28
- dizziness27
- oedema peripheral27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 13 |
| 2022 | 21 |
| 2023 | 12 |
| 2024 | 93 |
| 2025 | 330 |
| 2026 | 396 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,294 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| paronychiaSignal | 69 | 387.9 | 308.7 | 25,832 |
| dermatitis acneiformSignal | 31 | 124.5 | 88.0 | 3,658 |
| infusion related reactionSignal | 96 | 35.3 | 29.2 | 3,167 |
| neuropathy peripheralSignal | 53 | 13.6 | 10.4 | 606 |
| stomatitisSignal | 32 | 12.8 | 9.1 | 338 |
| rashSignal | 162 | 9.0 | 7.9 | 1,174 |
| oedema peripheralSignal | 27 | 5.4 | 3.7 | 93 |
| decreased appetiteSignal | 28 | 2.9 | 2.0 | 34 |
| pruritusSignal | 35 | 2.2 | 1.6 | 23 |
| off label use | 60 | 1.7 | 1.3 | 16 |
| diarrhoea | 41 | 1.5 | 1.1 | 8 |
| fatigue | 46 | 1.4 | 1.1 | 6 |
| dizziness | 27 | 1.3 | 0.9 | 2 |
| dyspnoea | 29 | 1.2 | 0.9 | 1 |
| nausea | 36 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.